Hsbc Holdings PLC Takes $52,000 Position in XBiotech Inc. $XBIT

Hsbc Holdings PLC bought a new stake in shares of XBiotech Inc. (NASDAQ:XBIT) in the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 15,984 shares of the biopharmaceutical company’s stock, valued at approximately $52,000. Hsbc Holdings PLC owned about 0.05% of XBiotech at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Nuveen LLC purchased a new position in shares of XBiotech during the 1st quarter valued at approximately $81,000. Charles Schwab Investment Management Inc. boosted its stake in shares of XBiotech by 15.3% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 8,918 shares during the last quarter. Deutsche Bank AG purchased a new position in shares of XBiotech during the 4th quarter valued at approximately $120,000. Bank of America Corp DE boosted its stake in shares of XBiotech by 42.0% during the 4th quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company’s stock valued at $79,000 after buying an additional 5,887 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in shares of XBiotech by 15.2% during the 4th quarter. Northern Trust Corp now owns 211,476 shares of the biopharmaceutical company’s stock valued at $835,000 after buying an additional 27,909 shares during the last quarter. 55.70% of the stock is currently owned by hedge funds and other institutional investors.

XBiotech Trading Down 2.0%

XBIT stock opened at $2.92 on Monday. The firm has a market cap of $89.03 million, a P/E ratio of -3.17 and a beta of 0.85. XBiotech Inc. has a 12-month low of $2.50 and a 12-month high of $8.32. The stock’s 50 day simple moving average is $3.04 and its 200 day simple moving average is $3.02.

XBiotech (NASDAQ:XBIT) last posted its quarterly earnings results on Wednesday, August 13th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter.

About XBiotech

XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.